research Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
Search
for
Sort by
Research
240-270 / 1000+ resultsresearch A Phase II Study of Vaginal Testosterone Cream (TEST) vs. Estring for Vaginal Dryness or Decreased Libido in Women with Early Stage Breast Cancer (BC) Treated with Aromatase Inhibitors (AIs).
Both vaginal testosterone cream and Estring effectively manage vaginal dryness in women with early-stage breast cancer on aromatase inhibitors.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Severe steroid-dependent idiopathic angioedema with response to rituximab
A woman with severe angioedema improved significantly after treatment with rituximab.
research Upadacitinib for Alopecia: Current Evidence and Clinical Insights
Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
research Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
research Drug Discovery Today: Therapeutic Strategies - 2006 Editorial
The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.
research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
research ENDOXAN ALOPECIA
Endoxan often causes hair loss, which usually starts in the third week of treatment.
research Influence of Different Designs of High-Heeled Shoes on Kinematics, Kinetics, and Muscle EMG of Female Gait
Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
research Dermatological adverse events with taxane chemotherapy
Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.
research Dutasteride: A Review of its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research 414 A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer
BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
research Effective treatment of female androgenic alopecia with dutasteride.
Dutasteride successfully treated a woman's hair loss when other treatments failed.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
research Sustaining treatment response in alopecia areata through tofacitinib dose tapering: A single-center retrospective study
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Daily subcutaneous testosterone for management of testosterone deficiency
Daily subcutaneous testosterone effectively restores testosterone levels in men.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
research Delphi Consensus on Attenuated Androgen Use for Long‐Term Prophylaxis in Hereditary Angioedema: AURA Project
The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.
research First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
research Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.